Wells Fargo & Company Kinnate Biopharma Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.24 - $2.66 $6 - $7	3 Added 2.13%	144 $0
Q4 2023 Feb 09, 2024	BUY	$1.07 - $2.5 $7 - $17	7 Added 5.22%	141 $0
Q3 2023 Nov 13, 2023	BUY	$1.38 - $3.31 $17 - $43	13 Added 10.74%	134 $0
Q2 2023 Aug 15, 2023	SELL	$2.33 - $6.84 $11,608 - $34,076	-4,982 Reduced 97.63%	121 $0
Q1 2023 May 12, 2023	BUY	$3.46 - $7.98 $16,611 - $38,311	4,801 Added 1589.74%	5,103 $31,000
Q4 2022 Feb 13, 2023	BUY	$5.26 - $12.19 $1,588 - $3,681	302 New	302 $1,000
Q2 2022 Aug 12, 2022	SELL	$7.43 - $13.0 $6,880 - $12,038	-926 Reduced 76.47%	285 $4,000
Q1 2022 May 16, 2022	SELL	$7.73 - $17.99 $82,826 - $192,762	-10,715 Reduced 89.85%	1,211 $14,000
Q4 2021 Feb 14, 2022	BUY	$16.5 - $25.48 $196,020 - $302,702	11,880 Added 25826.09%	11,926 $211,000
Q3 2021 Nov 15, 2021	SELL	$17.81 - $24.87 $1,656 - $2,312	-93 Reduced 66.91%	46 $1,000
Q2 2021 Aug 16, 2021	SELL	$22.19 - $31.55 $90,468 - $128,629	-4,077 Reduced 96.7%	139 $3,000
Q1 2021 May 13, 2021	BUY	$26.99 - $40.0 $113,789 - $168,640	4,216 New	4,216 $131,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.